Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Rise of Mid-Sized Pharma
2.
Contract Research Annual Review 2008
3.
Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023
4.
The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023
5.
Monoclonal Antibodies Report: 2008 Update
6.
Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major players
7.
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
8.
Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch
9.
Drug Repositioning Strategies - Serendipity by design
10.
Forecast Insight: Osteoarthritis - The COX-2 pipeline collapses
Best Sellers:
1.
BioNewsCast Press Release Distribution Service
2.
Immunogenicity to Biologics Implications of reactions against biotech drugs
3.
Neuro Stents & Coils Technology and Market Forecast
4.
Outsourcing in Drug Discovery, 3rd Edition
5.
American Hospital Register
6.
Professional Designation in Biopharmaceutical Technology - 3 Course Curriculum
7.
Outlook for RNAi, 2007 - siRNA and miRNA in biology, diagnostics and therapeutics
Biosimilars Series Strategic issues - Potential remains uncertain
Introduction
Significant barriers to entry into the biosimilars market exist. High up-front investment and the need for specific expertise favor big players. Understanding of the marketplace is critical for success acceptance by key stakeholders is crucial for market uptake of biosimilars and achieving preferential reimbursement status through constant review of the pricing strategy is desirable.
Scope
In-depth analysis of factors influencing market uptake of biosimilars Analysis of the pricing and reimbursement environment for biosimilars Detailed analysis of barriers to entry and strategies for success in the biosimilar market Overview of strategies for originators' market share protection
Highlights
Lack of automatic substitution with biosimilars means that intense promotion strategies need to be employed. Market uptake of biosimilars is highly dependent on acceptance by all key stakeholders especially physicians. All stakeholders need to be informed about biosimilars and various channels can be used. Payers' reaction to biosimilars is not known, but it is expected they will embrace them after a lag period. Standard incentives used to encourage generics use may not be applicable to biosimilars distributed in hospitals and alternative approaches need to be used. Barriers to entry remain high: high development and marketing costs compounded with the need for specialist expertise favor big players with strong financial backing and experience in branded generics industry. However smaller specialist players are well positioned to enter this market through co-development and co-marketing agreements.
Reasons to Purchase
Identify key stakeholders than need to be targeted in order to achieve high uptake of biosimilars Understand the pricing and reimbursement environment of biosimilars, barriers to entry and key strategies for success in the biosimilars market Gain insight into strategies employed by innovative pharmaceutical and biotechnology companies in order to maintain their market share
03-Oct-07 Format: PDF & SlidePack Pages: 104
Table of Contents
Price: $3,800.00 / GBP1,900.00
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.